Printer Friendly

History of posttransfusion hepatitis.

EARLY HISTORY OF POSTTRANSFUSION HEPATITIS (PT[H.sup.3]) During World War II and the immediate postwar period the demand for blood and blood components in the US increased substantially. This resulted in the establishment and growth of blood banks, transfusion services, and other blood and laboratory support services. The technology for collection, processing, and storage of whole blood and blood components materialized rapidly. By 1971, >5400 organizations were involved in the field of transfusion medicine with >12 million annual whole-blood donations and a nearly equal number of plasmapheresis donations (Table 1) [1].

PTH was first reported in the US by Beeson in 1943 [2]. Seven cases of PTH occurring 1-4 months after transfusion of blood or plasma were reported. The author commented that the expanding number of blood and plasma transfusions could lead to the occurrence of a considerable number of PTH cases. In 1964 Grady and Chalmers [3] reported the results of a retrospective study of PTH in nine Boston teaching hospitals, 1952-1962. In one of the hospitals 29% of the blood transfused was from commercial sources, while in the other eight hospitals blood only from volunteer blood donors was transfused. The incidence of clinically overt (i.e., symptomatic or icteric) PTH in recipients of blood products from volunteer blood donors was 0.6 cases/1000 units compared with 2.8 cases/1000 units in recipients of blood products from a mixture of volunteer and commercial blood donors.

In 1970 scientists at the NIH reported the results of a prospective study to determine the incidence of icteric and anicteric hepatitis in patients undergoing open-heart surgery [4]. During surgery the patients were given blood from either commercial or volunteer blood donors. Icteric and anicteric hepatitis developed in 51% of the recipients of commercial blood, whereas no hepatitis occurred in patients who received blood from volunteer donors. These authors estimated the hepatitis carrier rate for commercial blood donors to be 6.3% and for volunteer donors to be <0.6%. By 1971, the association between a paid blood donor and an increased risk of PTH was accepted by most, but not all, experts in the field. In early 1972, two states (California and Illinois) considered legislation to specifically eliminate payment for blood. The first law effective in eliminating paid blood donations was passed on October 1, 1972 (i.e., The Blood Labeling Act of Illinois). By the end of 1975, the Food and Drug Administration (FDA) mandated an all-voluntary blood donor system in which blood donors could not receive monetary payment for donations (Fig. 1) [1].

ROLE OF HEPATITIS B VIRUS (HBV) IN PTH

A viral etiology for PTH was long suspected. In 1965, Blumberg et al. [5] first described the Australia antigen and stated that this antigen could be identified in the sera of many hemophiliacs who had received multiple transfusions. Subsequently retrospective studies indicated that the presence of the Australia antigen in donor blood seemed to be clearly associated with the occurrence of PTH [6]. During an NIH Conference in 1970, additional evidence was presented that linked the presence of the Australia antigen to the occurrence of PTH. Furthermore, during this conference it was stated that the Australia antigen was part of an infectious agent, presumably a hepatitis virus [7]. Nevertheless, the screening of blood donors was not recommended. In a position paper written by Alter et al. [8], the authors recommended testing and deferral of blood donors based on the presence of the Australia antigen. (The Australia antigen is now referred to as hepatitis B surface antigen, HBsAg; ultimately the HBV was classified as a DNA virus in the Hepadnaviridae.) These recommendations were not implemented because of lack of consensus and concern over the general availability and variable detection limits of early-generation HBsAg assays.

In 1970, Gocke et al. [9], using retrospective studies, estimated that the exclusion of HBsAg-positive blood donors through either first- or second-generation assays (e.g., agar gel diffusion or counterelectrophoresis) would decrease the rate of PTH by -25%. The results of a prospective study on the effectiveness of exclusion of commercial and HBsAg-positive blood donors on the incidence of PTH was reported in 1972 X10]. The exclusion of HBsAg-positive blood resulted in a 25% reduction in the PTH rate, as predicted, while the elimination of commercial donors resulted in a 70% reduction in the PTH rate. With the simultaneous exclusion of commercial and HBsAg-positive donors, the PTH rate was reduced to 7.1% of the prior rate.

On the basis of these studies, screening of blood donations for HBsAg began in 1971 and became a US federal regulation in July 1972. The initial methods used to detect HBsAg were relatively insensitive (i.e., immunodiffusion and counterelectrophoresis), and transfusion-associated HBV cases continued to occur. In 1975, federal regulations were implemented requiring the screening of all donor blood for HBsAg by one of the third-generation tests [i.e., radioimmunoassay or enzyme-linked immunoassay (EIA)], as well as the labeling of blood components with respect to the volunteer or paid status of the donor. Since that time, virtually 100% of all blood used in single-component transfusions has been collected from volunteer donors. The transition to volunteer whole-blood donors and routine third-generation HbsAg testing of all blood donations resulted in a marked decrease in HBV-PTH, although occasional cases continue to occur [11]. In contrast to whole-blood donors, donors of plasma for further manufacture into plasma derivatives continue to be paid. The Cohen fractionation procedure used to prepare plasma derivatives dramatically reduces viral infectivity, and over the last decade, additional viral inactivation procedures (e.g., heating and detergent treatment) performed on these products render contemporary plasma derivatives virtually risk-free.

[FIGURE 1 OMITTED]

NON-A, NON-B PTH AND SURROGATE MARKERS In 1973, the causative agent of hepatitis A was detected by immune electron microscopy on stools from patients with acute food-borne hepatitis [12]. The hepatitis A virus (HAV) was later classified as a picomavirus closely related to the genus Enterovirus [13]. HAV is associated with acute resolving hepatitis without a chronic carrier state. Retrospective studies involving multiply transfused thalassemia patients indicated that these patients were at no greater risk of HAV infection than nontransfused children [14]. Similarly, analysis of donor and recipient samples from cases of PTH showed no evidence of involvement by HAV [15].

After implementation of specific screening tests for HBV and exclusion of HAV as a cause of PTH, it became clear that a substantial proportion of PTH cases continued to occur that were not caused by infections with HBV or other known viral agents. Termed non-A, non-B hepatitis (NANBH), this entity represented 90% of residual PTH cases in the US. In the late 1970s and early 1980s, rates of NANBH in multiply transfused patients were reported to be as high as 10%.

The results of the multicenter prospective Transfusion-Transmitted Viruses Study were published in 1981 [16]. Two major goals of this study were to define the incidence of PTH and to evaluate the factors influencing its occurrence. The data reported indicated a substantial association between recipients with NANBH and donor alanine aminotransferase (ALT) concentrations. Another independent study conducted at NIH confirmed an important association with an increased ALT concentration in donor blood and the development of NANBH in recipients of that blood [17]. Furthermore, in 1984 Stevens et al. [18], representing the Transfusion-Transmitted Viruses Study, reported an important association between the occurrence of NANBH in recipients of blood that tested positive for antibody to the core protein of HBV (anti-HBc). The research group at NIH confirmed this observation [19]. This study showed that anti-HBc testing of donors, in concert with ALT testing, might eliminate 30-50% of recipient NANBH. Primarily on the basis of these studies, in 1986-87 blood collection agencies began screening donated blood for surrogate markers of NANBH (anti-HBc and ALT) [20]. The rate of PTH among recipients dropped subsequently to as low as 2-3% [21].

HCV AS MAJOR ETIOLOGICAL AGENT OF NANBH

Extensive research was conducted in the 1970s and 1980s to identify the etiological agent(s) of NANBH. More than 25 preliminary reports of associated agents were determined to be false. Then, in 1988, the hepatitis C virus (HCV) was identified with molecular biology techniques by M. Houghton and associates at Chiron, in collaboration with D. W. Bradley of the Hepatitis Branch of the Centers for Disease Control [22]. The process of virus discovery involved construction of a cDNA expression library in the bacteriophage kgt11 by using high-titer plasma from a chimpanzee inoculated with PTH plasma. The library was then screened for rare clones expressing viral antigen with serum from a chronic NANBH patient as a presumed source of viral antibodies. Screening of this library led to the identification of the positive cDNA clone 5-1-1 (Fig. 2) [23].

HCV is a single-stranded positive-sense RNA virus with a genome of ~9500 bases coding for ~3000 amino acids. This small RNA lipid-envelope [24] virus has been classified in the family Flaviviridae. The entire viral genome was sequenced within 1 year, and antigens were expressed for development of antibody detection assays. Early studies established that HCV was the etiological agent of at least 80-90% of residual NANBH [21].

HCV SCREENING ASSAYS AND RESIDUAL RISK OF HCV-PTH

Blood collection agencies in the US implemented donor screening immediately after licensure of the first-generation anti-HCV enzyme immunoassay (HCV 1.0 EIA) in 1990. This EIA detected antibodies to an antigenic protein (c100-3) of HCV (Fig. 2). Even though this assay facilitated the screening of blood donors for anti-HCV antibodies, it did not detect all infectious blood donations [25] and had a protracted window of infectivity ranging from 12 weeks to >26 weeks postinfection [26]. Nevertheless, a prospective study of patients receiving transfusions before and after mid-1990 found that the risk of transfusion-associated HCV infection per unit dropped from 0.36% (1 in 274) before anti-HCV screening to 0.07% (1 in 3300) for donations screened with both surrogate markers and first-generation anti-HCV tests [27,28]. It has since been estimated that this test prevented transmission of HCV to 40 000 patients per year in the US [21].

[FIGURE 2 OMITTED]

A second-generation anti-HCV EIA (HCV 2.0 EIA) was licensed and rapidly implemented in 1992. This test incorporated two additional proteins, one structural (c22-3) and one nonstructural (c33c) (Fig. 2). This test was substantially more sensitive than HCV 1.0 EIA in detecting acute and chronic HCV infections. Antibodies to these proteins generally appear much earlier than those to c100-3, so the seroconversion window period could be shortened by 10-20 days. In addition, parallel studies comparing first- and second-generation tests showed that HCV 2.0 EIA detected additional HCV chronically infected donors at a rate of 1 in 1000 [25]. This increased yield translated into prevention of an additional 13 000 HCV transmissions per year by transfusion [21]. Conflicting estimates existed regarding the residual risk of HCV after implementation of the second-generation assay. Projections based on incidence-window period models suggested that the risk of HCV PTH had dropped to as low as 1 in 100 000 per unit [29], whereas extrapolation from historical PTH studies suggested a risk of up to 1 in 5000 [30].

In 1996, a third-generation screening test (HCV 3.0 EIA) was licensed that detected antibodies to an even greater number of HCV-encoded epitopes. This test differs in antigen content from the earlier-generation screening assays with deletion of the c-100 recombinant protein and addition of the NS-5 recombinant protein (Fig. 2). This allows detection of antibodies to a greater number of HCV-encoded epitopes. HCV 3.0 EIA has consequently narrowed the seroconversion window by about 10 days relative to the HCV 2.0 EIA [31,32]. This window period reduction is projected to detect 1-2 additional seroconverting donors per million units screened. Although the impact of the HCV 3.0 EIA on residual HCV risk has not been prospectively quantified, the ongoing NIH prospective study of PTH has failed to detect any HCV transmissions among >650 patients transfused with >2500 units of blood screened by second-generation HCV EIA since late 1992 (H. Alter, personal communication).

HCV CONFIRMATORY ASSAYS

Given the low prevalence of viral infection in preselected volunteer donors, it is important that confirmatory assays are developed and used to discriminate between true and falsely positive EIA-reactive donors. The Chiron RIBA[TM] HCV 2.0 strip immunoassay (RIBA 2.0) was licensed on June 27, 1993. The RIBA 2.0 is an immunoblot assay in which four recombinant HCV-encoded antigens fused to human superoxide dismutase are immobilized on nitrocellulose strips. A negative, indeterminate, or positive interpretation is based on the reaction pattern present on the strip. About 89% of RIBA 2.0-positive specimens are HCV RNA-positive by PCR tests, while -19% of RIBA 2.0-indeterminate specimens are HCV RNA-positive by PCR tests [25].

The HCV 3.0 EIA companion supplemental test, Chiron RIBA HCV 3.0 SIA (RIBA 3.0), is now pending licensure from the FDA. This assay uses a mixture of peptides, rather than recombinant antigens, for the 5-1-1/ c-100 and c22-3 regions of the HCV genome. The use of peptides, when appropriate, eliminates those amino acid sequences that are a source of nonspecific cross-reactivity with other antigens X33, 341. On the basis of data from Europe [35], these changes have substantially improved this assay's lowest detection limits and specificity.

The prevalence of anti-HCV antibody in US blood donors, as determined with HCV 2.0 and 3.0 EIA confirmed by RIBA 2.0 and 3.0, respectively, ranges from 0.2% to 0.4% [21]. At least 70% of seropositive donors are viremic [25]. Similar rates have been observed in Europe, and higher rates in Japan and other Asian countries. Importantly, these rates are in highly selected blood donors [26]. The prevalence of HCV infection in the general population of the US is currently estimated to be between 1% and 2% [36].

RETENTION OF SURROGATE TESTS

With virtual elimination of NANBH by HCV screening, the issue of whether surrogate tests should be retained has surfaced. Although the direct cost of ALT testing is low, the indirect cost is very high because >1% of units test positive and are discarded. Anti-HBc screening has a higher direct cost and results in ~0.5% unit loss. Furthermore, the donors of these units are either temporarily or permanently deferred. The preponderance of available data indicates that, in the presence of anti-HCV testing, retention of ALT testing prevents few if any residual PTH cases [30,37]. Therefore, a 1995 NIH Consensus Statement recommended that ALT testing of volunteer blood donors be discontinued. On the other hand, the consensus conference recommended that anti-HBc testing be retained, at least temporarily, for the following reasons: possible prevention of some PTH HBV cases and possible prevention of some cases of transfusion-transmitted HIV from donors who test negative for anti-HIV during the window phase of infection [20]. Recent studies suggest that these applications of anti-HBc have a very low predictive value and very poor cost effectiveness [37]. Therefore, discontinuation of anti-HBc is being actively reconsidered.

HEPATITIS G VIRUS (HGV) AND OTHER PUTATIVE PTH AGENTS

Evidence indicates that additional viruses that explain rare residual PTH cases may exist. Indeed, before HCV was identified there was strong suspicion that more than one blood-borne viral agent was causing NANBH [26]. However, it has now become clear that reinfection by different HCV strains is not uncommon, which explains many of the cases of recurrent PTH that led to speculation regarding multiple agents. In addition, the rate of non-ABC hepatitis in recipients is now comparable with that in nontransfusion controls (i.e., <0.8% in both US and Canadian studies, similar to background values) [20]. Nevertheless, the search for additional agents has continued.

In 1995, researchers at Abbott Laboratories reported the isolation of three viral agents [GB viruses (GBV) A, B, and C] from tamarins inoculated with serum from a surgeon "GB" who had contracted acute icteric hepatitis 20 years earlier X38, 391. Only one of the isolates (GBV-C) proved to be a human viral hepatitis candidate; the other two were tamarin agents incidentally infecting the animals at the time of the experiments. A second independent group of researchers from GeneLabs performed molecular cloning with plasma from a patient designated PNF2161, who was originally identified by the CDC as having NANBH. The virus cloned by these researchers was designated HGV [40]. Given the amino acid sequence matching of 95% between GBV-C and HGV, these viruses are therefore considered to be different strains of the same virus, tentatively termed GBV-C/HGV [41]. GBV-C/HGV is a positive-stranded RNA virus classified in the Flaviviridae, the same family as HCV. Only 32% amino acid homology exists between GBV-C/HGV and HCV. Therefore, although GBV-C/HGV is distantly related to HCV, this agent is not a different serotype of HCV.

GBV-C/HGV RNA has been detected at a high prevalence (2-25%) among various high-risk groups, e.g., intravenous drug users, hemophiliacs, and hemodialysis patients. About 1-2% of blood donors have also been found to be RNA-positive [42]. A recent study, using PCR technology, clarified the relationship of GBV-C/HGV and the occurrence of hepatitis [43]. PCR was performed on selected patients from a surveillance study of acute viral hepatitis in four US counties. The patients included in this study were: 45 patients with a diagnosis of non-A-E hepatitis, 116 patients with hepatitis C, 100 patients with hepatitis A, and 100 patients with hepatitis B. The results of this study indicated that HGV was implicated as a potential etiological agent in only 0.3% of cases. These HGV cases had only mild liver enzyme increases. Furthermore, coinfection by HGV did not affect the clinical course in patients with hepatitis A, B, or C.

Initial studies involving the prevalence of GBV-C/ HGV infection were hampered by the absence of an antibody detection system; therefore, the diagnosis of GBV-C/HGV infection depended on the use of PCR to detect GBV-C/HGV RNA. Recently an antibody test has been developed that has demonstrated seroconversion associated with viral RNA clearance in about two-thirds of infected persons [44, 45].

GBV-C/HGV is unequivocally a highly prevalent transfusion-transmissible agent [46]. However, a causal relationship between HGV infection and hepatitis or other diseases has not been established [41, 43]. GBV-C/HGV appears to explain only a small fraction of either transfusion-or community-acquired hepatitis cases, and these cases are very mild X43, 461. Thus at present, it is unclear whether screening of blood donors for GBV-C/HGV will be recommended.

The overall risk of PTH has declined markedly over the past 2 decades with virtual elimination of transmission of HBV and HCV infections. The advances in prevention of PTH have been not only extraordinary with regard to recipient safety, but also highly cost-effective. Indeed, the cost of screening the blood donor population for HCV is more than offset by the reduced healthcare costs achieved by prevention of PTH cases X30]. Unfortunately, many infections did occur before the availability of screening assays. The tragedy of the transfusion AIDS epidemic also echos loudly. Thus, the current priority of infectious disease blood banks is further enhancement of blood safety, through elimination of rare residual cases of virally transmitted hepatitis by implementation of nucleic acid screening assays X47] and avoidance of complacency through proactive surveillance of the blood supply for new or emerging infectious agents.

Received March 3, 1997; revised April 18, 1997; accepted April 29, 1997.

References

[1.] Domen RE. Paid-versus-volunteer blood donation in the United States: a historical review. Transfus Med Rev 1995;9:53-9.

[2.] Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA 1943;121: 1332-4.

[3.] Grady GF, Chalmers TC. Risk of post-transfusion viral hepatitis. N Engl J Med 1964;271:337-42.

[4.] Walsh JH, Purcell RH, Morrow AG, Chanock RM, Schmidt PJ. Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA 1970;211:261-5.

[5.] Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965;191:541-6.

[6.] Gocke DJ, Greenberg HB, Kavey NB. Hepatitis antigen. Detection of infectious blood donors. Lancet 1969;1:248-9.

[7.] NIH Conference. Viral hepatitis (edited transcript, Combined Clinical Staff Conference). Ann Intern Med 1970;72:257-69.

[8.] Alter HJ, Holland PV, Schmidt PJ. Hepatitis-associated antigen. To test or not to test? Lancet 1970;ii:142-3.

[9.] Gocke DJ, Greenberg HB, Kavey NB. Correlation of Australia antigen with posttransfusion hepatitis. JAMA 1970;77:877-9.

[10.] Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, Schmidt PJ. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972;77:691-9.

[11.] Hoofnagle JH. Posttransfusion hepatitis B [Editorial]. Transfusion 1990;30:384-6.

[12.] Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A. Detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science 1973;182:1026-8.

[13.] Gust ID, Coulepis AG, Feinstone SM, Locarnini SA, Moritsugu Y, Najera R, Siegl G. Taxonomic classification of hepatitis A virus. Intervirology 1983;20:1-7.

[14.] Stevens CE, Silbert JA, Miller DR, Dienstag JL, Purcell RH, Szmuness W. Serologic evidence of hepatitis A and B virus infections in thalassemia patients: a retrospective study. Transfusion 1978;18:356-60.

[15.] Dienstag JL, Purcell HR, Alter HJ, Feinstone SM, Wong DC, Holland PV. Non-A, non-B post-transfusion hepatitis. Lancet 1977;1: 560-2.

[16.] Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients. The Transfusion-Transmitted Viruses Study. N Engl J Med 1981;4: 989-94.

[17.] Alter HJ, Purcell RH, Holland PV, Ailing DW, Koziol DE. Donor transaminase and recipient hepatitis. JAMA 1981;246:630-4.

[18.] Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Kahn R, et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med 1984;101:733-8.

[19.] Koziol DE, Holland PV, Ailing DW, Melpolder JC, Solomon RE, Purcell RH, et al. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med 1986;104:488-95.

[20.] Infectious disease testing for blood transfusions. NIH Consensus Statement Jan 9-11, 1995;13:1-27.

[21.] Alter HJ. To C or not to C: these are the questions. Blood 1995;85:1681-95.

[22.] Ezzell C. Candidate cause identified of non-A, non-B hepatitis [News]. Nature 1988;333:195.

[23.] Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-61.

[24.] Feinstone SM, Mihalik KB, Kamimura T, Alter HJ, London WT, Purcell RH. Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect Immun 1983;41:816-21.

[25.] Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, Nelles M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992;32:805-13.

[26.] Alter H. Transfusion-transmitted non-A, non-B and hepatitis C virus infections. In: Rossi EC, Simon TL, Moss GS, Gould SA, eds. Principles of transfusion medicine, 2nd ed. Baltimore: Williams & Wilkins, 1996:687-98.

[27.] Donahue JG, Munoz A, Ness PM, Brown DE, Yawn DH, McAllister HA, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.

[28.] Nelson KE, Ahmed F, Stambolis V, Ness PM, Yawn D, McAllister H. Incident hepatitis C virus (HCV) and hepatitis B virus (HBV) infections in transfused cardiac surgery patients: infection rates during different methods of donor screening [Abstract]. NIH Consensus Development Conference on Infectious Disease Testing for Blood Transfusions. Program and Abstracts Book 1995:67-9.

[29.] Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334: 1685-90.

[30.] Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. Transfusion 1995;35:903-10.

[31.] Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-8.

[32.] Courouce AM, Le Marrec N, Girault A, Ducamp S, Simon N. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994;34:790-5.

[33.] Tobler LH, Busch MP, Wilber J, Dinello R, Quan S, Polito A, et al. Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion 1994;34:130-4.

[34.] Tobler LH, Busch MP, Peterson J, Kochesky R, Bahl C, Lee SR. Identification of a crossreactive epitope within hepatitis C virus core antigen: resolution by third-generation hepatitis C virus assays [Letter]. Transfusion 1996;36:581-2.

[35.] Damen M, Zaaijer HL, Cuypers HTM, Vrielink H, van der Poel CL, Reesink HW, Lelie PN. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995; 35:745-9.

[36.] Gretch DR, dela Rosa C, Carithers RL Jr, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995;123:321-9.

[37.] Mosley JW, Huang W, Stram D0, Nowicki MJ, Hollinger FB, Aach RD, et al. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes. Transfusion 1996;36: 776-81.

[38.] Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci U S A 1995;92: 3401-5.

[39.] Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995;1:564-9.

[40.] Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271: 505-8.

[41.] Zuckerman AJ. Alphabet of hepatitis viruses [Commentary]. Lancet 1996;347:558-9.

[42.] Di Bisceglie AM. Hepatitis G virus infection: a work in progress. Ann Intern Med 1996;125:772-3.

[43.] Alter MJ, Gallagher M, Morris TT, Moyer LA, Meeks EL, Krawczynski K, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997;336: 741-6.

[44.] Pilot-Matias TJ, Carrick RJ, Coleman PF, Leary TP, Surowy TK, Simons JN, et al. Expression of the GB virus C E2 glycoprotein using the Semliki forest virus vector system and its utility as a serologic marker. Virology 1996;225:282-92.

[45.] Dille BJ, Surowy TK, Gutierrez RA, Coleman PF, Knigge MF, Carrick RJ, et al. An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis 1997;175:458-61.

[46.] Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih JW, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336: 747-54.

[47.] Busch MP. Application of molecular biology to infectious disease screening of blood donors. In: Allen RW, AuBuchon JP, eds. Molecular genetics in diagnosis and research. Bethesda, MD: American Association of Blood Banks, 1995:111-38.

[3] Nonstandard abbreviations: PTH, posttransfusion hepatitis; H AV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HGV, hepatitis G virus; GBV-C, GB virus C; HBsAg, hepatitis B virus surface antigen; EIA, enzyme-linked immunoassay; NANBH, non-A, non-B hepatitis; ALT, alanine aminotransferase; PCR, polymerase chain reaction.

Leslie H. Tobler (1) * and Michael P. Busch (1,2)

(1) Irwin Memorial Blood Centers, 270 Masonic Ave., San Francisco, CA 94118, and (2) Department of Laboratory Medicine, University of California, San Francisco, CA 94143.

* Author for correspondence. Fax 415-775-3859; e-mail ltobler@ccnet.com.
Table 1. Events in understanding and minimizing PTH.

Date Event Reference

 HBV and paid vs. nonpaid donors

1943 First US report of PTH 2
1964 Retrospective study: paid vs nonpaid donors on 3
 rate of PTH
1965 Discovery of HBV antigen (Australia antigen) 5
1970 Prospective study evaluating the contribution 4
 of paid vs nonpaid donors to the rate of PTH
1970 HBsAg as marker for PTH 69
1972 Prospective study: effectiveness of exclusion 10
 of commercial and HBsAg-positive blood
 donors on the incidence of PTH
1972 FDA mandates screening of all blood donations 11
 for HBsAg

 NANBH and surrogate markers

1973 HAV discovered 12
 HAV not causative agent of PTH; NANBH defined 1,415
1975 FDA mandates an all-voluntary blood donor 1
 system
1975 FDA mandates use of a third generation HBsAg 11
 assay
1981 Transfusion-Transmitted Virus Study results 16
 suggest use of ALT as surrogate marker
 for PTH
1981 Results of NIH study confirm association 17
 between increased ALT concentration in
 donor blood
 and the development of recipient PT-NANBH
1986-87 Implementation of surrogate marker testing 1,819

 HCV: primary cause of NANBH

1988 Discovery of HCV 2,223
1989 Classification of HCV as a single-stranded 23
 positive-sense RNA virus belonging to the
 family Flaviviridae
1990 Licensing and implementation of first-
 generation HCV screening
1992 Licensing and implementation of second-
 generation HCV screening
1993 Licensing of HCV supplemental testing
1995 Studies show declining value of surrogate 3,037
 markers

 Recent events post-HCV screening

1995 NIH Consensus Statement recommends 20
 discontinuation of ALT testing,
 continuation of anti-HBc testing
1995 Discovery of GBV-C/HGV 38-41
1995 GBV-C/HGV transfusion-transmission established 40,424,346
1996 Licensing and partial implementation of
 third-generation HCV screening
COPYRIGHT 1997 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Beckman Conference
Author:Tobler, Leslie H.; Busch, Michael P.
Publication:Clinical Chemistry
Date:Aug 1, 1997
Words:4940
Previous Article:Molecular biological methods in diagnosis and treatment of liver diseases.
Next Article:Type A viral hepatitis: epidemiology, diagnosis, and prevention.
Topics:


Related Articles
HCV Risks by Design. (Clinical Capsules).
NIH consensus statement surveys hepatitis B care.
Raging hormones: closing the loop from bench to bedside. The twenty-second Arnold O. Beckman Conference in clinical chemistry.
Advances in Clinical Laboratory Hematology. The twenty-third Arnold O. Beckman Conference in Clinical Chemistry.
Liver diseases and the clinical laboratory--the twentieth Arnold O. Beckman conference in clinical chemistry.
Acute coronary syndromes: from bench to bedside--the twenty-first annual Arnold O. Beckman Conference in Clinical Chemistry.
AACC meetings.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |